Antje Blank

2.9k total citations
68 papers, 1.7k citations indexed

About

Antje Blank is a scholar working on Oncology, Epidemiology and Pharmacology. According to data from OpenAlex, Antje Blank has authored 68 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 17 papers in Epidemiology and 14 papers in Pharmacology. Recurrent topics in Antje Blank's work include Pharmacogenetics and Drug Metabolism (14 papers), Hepatitis B Virus Studies (14 papers) and Drug Transport and Resistance Mechanisms (11 papers). Antje Blank is often cited by papers focused on Pharmacogenetics and Drug Metabolism (14 papers), Hepatitis B Virus Studies (14 papers) and Drug Transport and Resistance Mechanisms (11 papers). Antje Blank collaborates with scholars based in Germany, Tanzania and Ghana. Antje Blank's co-authors include Walter E. Haefeli, Stephan Urban, Matthias Schwab, Mathias Haag, Gerd Mikus, Jürgen Burhenne, Thorsten Lehr, A. A. Alexandrov, Nicolas Hohmann and Pavel Bogomolov and has published in prestigious journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Antje Blank

65 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antje Blank Germany	20	785	544	291	256	232	68	1.7k
Max Moldovan Australia	20	1.1k 1.4×	1.3k 2.3×	198 0.7×	306 1.2×	294 1.3×	48	2.6k
Kathleen N. Ly United States	16	1.7k 2.2×	1.7k 3.1×	271 0.9×	175 0.7×	62 0.3×	30	2.5k
Craig Mowat United Kingdom	21	1.1k 1.4×	225 0.4×	535 1.8×	199 0.8×	194 0.8×	75	2.9k
Olufunmilayo Lesi Nigeria	25	1.3k 1.7×	1.2k 2.3×	450 1.5×	569 2.2×	156 0.7×	65	2.7k
Sameera Ezzat Egypt	19	347 0.4×	290 0.5×	157 0.5×	363 1.4×	110 0.5×	64	1.3k
Getnet Yimer Ethiopia	21	366 0.5×	135 0.2×	214 0.7×	122 0.5×	70 0.3×	84	1.4k
Hartwig Klinker Germany	31	1.6k 2.1×	1.3k 2.4×	207 0.7×	279 1.1×	148 0.6×	157	2.9k
Fei Yu China	22	538 0.7×	486 0.9×	189 0.6×	489 1.9×	228 1.0×	88	2.0k
Gary P. Jeffrey Australia	32	2.5k 3.2×	2.3k 4.2×	237 0.8×	415 1.6×	212 0.9×	138	4.5k
Marco Montagnani Italy	23	497 0.6×	366 0.7×	375 1.3×	180 0.7×	77 0.3×	65	1.5k

Countries citing papers authored by Antje Blank

Since Specialization

Citations

This map shows the geographic impact of Antje Blank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antje Blank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antje Blank more than expected).

Fields of papers citing papers by Antje Blank

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antje Blank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antje Blank. The network helps show where Antje Blank may publish in the future.

Co-authorship network of co-authors of Antje Blank

This figure shows the co-authorship network connecting the top 25 collaborators of Antje Blank. A scholar is included among the top collaborators of Antje Blank based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antje Blank. Antje Blank is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burhenne, Jürgen, Kathrin I. Foerster, David Czock, et al.. (2025). Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteers. Frontiers in Pharmacology. 16. 1542063–1542063.

Lampertico, Pietro, Pavel Bogomolov, Vladimir Chulanov, et al.. (2025). Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg‐IFNα‐2a as Treatment for Chronic Hepatitis Delta. Liver International. 45(2). e70008–e70008. 3 indexed citations

Sauter, Max, et al.. (2025). Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers. Pharmaceutics. 17(1). 60–60. 1 indexed citations

Sauter, Max, Andreas D. Meid, Jürgen Burhenne, et al.. (2024). Effect of Tacrolimus Formulation (Prolonged‐Release vs Immediate‐Release) on Its Susceptibility to Drug‐Drug Interactions with St. John's Wort. Clinical Pharmacology in Drug Development. 13(3). 297–306. 2 indexed citations

Foerster, Kathrin I., Jürgen Burhenne, Martin Schulz, et al.. (2024). Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers. Clinical Pharmacokinetics. 63(4). 469–481. 2 indexed citations

Hohmann, Nicolas, et al.. (2024). Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin. Clinical and Translational Science. 17(8). e70007–e70007. 7 indexed citations

Rigalli, Juan Pablo, Antje Blank, Jürgen Burhenne, et al.. (2024). Extracellular Vesicles as Surrogates for the Regulation of the Drug Transporters ABCC2 (MRP2) and ABCG2 (BCRP). International Journal of Molecular Sciences. 25(7). 4118–4118. 3 indexed citations

Wiedmann, Felix, Fitzwilliam Seibertz, Timon Seeger, et al.. (2024). Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Research in Cardiology. 119(1). 93–112. 21 indexed citations

Burhenne, Jürgen, Johanna Weiß, Mathias Haag, et al.. (2023). Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers. Frontiers in Pharmacology. 14. 1128547–1128547. 4 indexed citations

10.

Benzinger, Petra, Kathrin I. Foerster, Jürgen Burhenne, et al.. (2023). Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study. Drugs & Aging. 40(2). 153–164. 1 indexed citations

11.

Taylor, Lenka A., Torsten Hoppe‐Tichy, Jürgen Burhenne, et al.. (2023). Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers. British Journal of Clinical Pharmacology. 89(8). 2458–2464. 8 indexed citations

12.

Blank, Antje, Andreas D. Meid, Kathrin I. Foerster, et al.. (2023). CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults. Clinical Pharmacokinetics. 62(9). 1305–1314. 4 indexed citations

13.

Foerster, Kathrin I., Antje Blank, Peter W. Rose, et al.. (2022). Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. European Journal of Clinical Pharmacology. 78(6). 975–987. 4 indexed citations

14.

Taylor, Lenka A., Torsten Hoppe‐Tichy, Jürgen Burhenne, et al.. (2022). Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers. European Journal of Clinical Pharmacology. 78(12). 1965–1972. 7 indexed citations

15.

Burghaus, Ina, Max Sauter, Peter W. Rose, et al.. (2022). Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide—An Exploratory Phase I Clinical Trial. International Journal of Molecular Sciences. 23(24). 15924–15924. 5 indexed citations

16.

Foerster, Kathrin I., et al.. (2021). Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clinical Pharmacokinetics. 61(1). 97–109. 10 indexed citations

17.

Blank, Antje, et al.. (2020). Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. Clinical Pharmacokinetics. 59(7). 927–939. 12 indexed citations

18.

Rose, Peter W., et al.. (2020). Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. The Journal of Clinical Pharmacology. 61(4). 472–479. 6 indexed citations

19.

Hohmann, Nicolas, Antje Blank, Jürgen Burhenne, et al.. (2019). Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. British Journal of Clinical Pharmacology. 85(10). 2310–2320. 13 indexed citations

20.

Hohmann, Nicolas, Antje Blank, Johanna Weiß, et al.. (2017). Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics. British Journal of Clinical Pharmacology. 83(9). 1954–1965. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact